Affymax, Inc.  

(Public, OTCMKTS:AFFY)   Watch this stock  
Find more results for AFFY
May 22 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.07 - 0.74
Open     -
Vol / Avg. 0.00/50,100.00
Mkt cap 3.38M
P/E 1.26
Div/yield 0.05
EPS 0.07
Shares 37.49M
Beta 2.23
Inst. own 0%

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 17164.29% -1053.62%
Operating margin -2269.05% -1099.05%
EBITD margin - -2724.25%
Return on average assets 488.14% -22.96%
Return on average equity 2040.59% -420.95%
Employees 4 -
CDP Score - -


Suite 240, 19200 Stevens Creek Blvd
United States - Map
+1-650-8128700 (Phone)
+1-650-4240832 (Fax)

Website links


Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.

Officers and directors

John A. Orwin Independent Chairman of the Board
Age: 50
Jonathan M. Couchman President, Chief Executive Officer, Director
Age: 44
Mark G. Thompson Chief Financial Officer
Age: 53
Grace U. Shin J.D. General Counsel
Age: 50